Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study

Psychiatry and Clinical Neurosciences

Volumn 72, Issue 6, 2018, Pages 445-453

  Ishigooka, Jun ^a   Iwashita, Shuichi ^b   Tadori, Yoshihiro ^b  

^a Institute of CNS Pharmacology   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

brexpiprazole; Japan; long term; safety; schizophrenia

Indexed keywords

BREXPIPRAZOLE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AKATHISIA; ARTICLE; BACKACHE; BODY WEIGHT GAIN; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; HEADACHE; HUMAN; INSOMNIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SOMNOLENCE; SUICIDAL IDEATION; TREMOR; AGED; CLINICAL TRIAL; JAPAN;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUINOLONES; SCHIZOPHRENIA; THIOPHENES;

EID: 85046026627     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12654     Document Type: Article

References (15)

1. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013; 13: 50.
2. Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 2013; 14: 2–44.
3. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.
4. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A III, Assunção-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 2009; 70: 627–643.
5. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2012; 8: 114–126.
6. Correll CU. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25 (Suppl. 2): S12–S21.
7. DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012; 12: 20.
8. Maeda K, Sugino H, Akazawa H et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014; 350: 589–604.
9. Correll CU, Skuban A, Ouyang J et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2015; 172: 870–880.
10. Kane JM, Skuban A, Ouyang J et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr. Res. 2015; 164: 127–135.
11. Fleischhacker WW, Hobart M, Ouyang J et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: A randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 2017; 20: 11–21.
12. Kane JM, Skuban A, Hobart M et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr. Res. 2016; 174: 93–98.
13. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J. Clin. Psychiatry 1997; 58: 538–546.
14. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.) 2006; 189: 259–266.
15. Kramer M, Simpson G, Maciulis V et al. One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia. CNS Spectr. 2010; 15: 506–514.